Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2022

24-11-2021

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials

Auteurs: Benjamin Cuer, Thierry Conroy, Beata Juzyna, Sophie Gourgou, Caroline Mollevi, Célia Touraine

Gepubliceerd in: Quality of Life Research | Uitgave 5/2022

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Health-related quality of life (HRQoL) is an important endpoint in cancer clinical trials. Analysis of HRQoL longitudinal data is plagued by missing data, notably due to dropout. Joint models are increasingly receiving attention for modelling longitudinal outcomes and the time-to-dropout. However, dropout can be informative or non-informative depending on the cause.

Methods

We propose using a joint model that includes a competing risks sub-model for the cause-specific time-to-dropout. We compared a competing risks joint model (CR JM) that distinguishes between two causes of dropout with a standard joint model (SJM) that treats all the dropouts equally. First, we applied the CR JM and SJM to data from 267 patients with advanced oesophageal cancer from the randomized clinical trial PRODIGE 5/ACCORD 17 to analyse HRQoL data in the presence of dropouts unrelated and related to a clinical event. Then, we compared the models using a simulation study.

Results

We showed that the CR JM performed as well as the SJM in situations where the risk of dropout was the same whatever the cause. In the presence of both informative and non-informative dropouts, only the SJM estimations were biased, impacting the HRQoL estimated parameters.

Conclusion

The systematic collection of the reasons for dropout in clinical trials would facilitate the use of CR JMs, which could be a satisfactory approach to analysing HRQoL data in presence of both informative and non-informative dropout. Trial registration: This study is registered with ClinicalTrials.gov, number NCT00861094.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Laird, N. M., & Ware, J. H. (1982). Random-effects models for longitudinal data. Biometrics, 38, 963–974.CrossRef Laird, N. M., & Ware, J. H. (1982). Random-effects models for longitudinal data. Biometrics, 38, 963–974.CrossRef
2.
go back to reference Chen, H., & Cohen, P. (2006). Using individual growth model to analyze the change in quality of life from adolescence to adulthood. Health and Quality of Life Outcomes, 4, 10.CrossRef Chen, H., & Cohen, P. (2006). Using individual growth model to analyze the change in quality of life from adolescence to adulthood. Health and Quality of Life Outcomes, 4, 10.CrossRef
3.
go back to reference Bell, M. L., Kenward, M. G., Fairclough, D. L., et al. (2013). Differential dropout and bias in randomised controlled trials: when it matters and when it may not. Bmj, 346, e8668CrossRef Bell, M. L., Kenward, M. G., Fairclough, D. L., et al. (2013). Differential dropout and bias in randomised controlled trials: when it matters and when it may not. Bmj, 346, e8668CrossRef
4.
go back to reference Henderson, R., Diggle, P., & Dobson, A. (2000). Joint modelling of longitudinal measurements and event time data. Biostatistics, 1, 465–480.CrossRef Henderson, R., Diggle, P., & Dobson, A. (2000). Joint modelling of longitudinal measurements and event time data. Biostatistics, 1, 465–480.CrossRef
5.
go back to reference Ibrahim, J. G., Chu, H., & Chen, L. M. (2010). Basic concepts and methods for joint models of longitudinal and survival data. Journal of Clinical Oncology, 28, 2796–2801.CrossRef Ibrahim, J. G., Chu, H., & Chen, L. M. (2010). Basic concepts and methods for joint models of longitudinal and survival data. Journal of Clinical Oncology, 28, 2796–2801.CrossRef
6.
go back to reference Cuer, B., Mollevi, C., Anota, A., et al. (2020). Handling informative dropout in longitudinal analysis of health-related quality of life: Application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17. BMC Medical Research Methodology, 20, 223.CrossRef Cuer, B., Mollevi, C., Anota, A., et al. (2020). Handling informative dropout in longitudinal analysis of health-related quality of life: Application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17. BMC Medical Research Methodology, 20, 223.CrossRef
7.
go back to reference Tsiatis, A. A., & Davidian, M. (2004). Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica, 809–834. Tsiatis, A. A., & Davidian, M. (2004). Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica, 809–834.
8.
go back to reference Fielding, S., Fayers, P. M., Loge, J. H., et al. (2006). Methods for handling missing data in palliative care research. Palliative Medicine, 20, 791–798.CrossRef Fielding, S., Fayers, P. M., Loge, J. H., et al. (2006). Methods for handling missing data in palliative care research. Palliative Medicine, 20, 791–798.CrossRef
9.
go back to reference Bernhard, J., Cella, D. F., Coates, A. S., et al. (1998). Missing quality of life data in cancer clinical trials: Serious problems and challenges. Statistics in Medicine, 17, 517–532.CrossRef Bernhard, J., Cella, D. F., Coates, A. S., et al. (1998). Missing quality of life data in cancer clinical trials: Serious problems and challenges. Statistics in Medicine, 17, 517–532.CrossRef
10.
go back to reference Elashoff, R., Li, G., & Li, N. (2016). Joint modeling of longitudinal and time-to-event data. CRC Press.CrossRef Elashoff, R., Li, G., & Li, N. (2016). Joint modeling of longitudinal and time-to-event data. CRC Press.CrossRef
11.
go back to reference Williamson, P. R., Kolamunnage-Dona, R., Philipson, P., et al. (2008). Joint modelling of longitudinal and competing risks data. Statistics in Medicine, 27, 6426–6438.CrossRef Williamson, P. R., Kolamunnage-Dona, R., Philipson, P., et al. (2008). Joint modelling of longitudinal and competing risks data. Statistics in Medicine, 27, 6426–6438.CrossRef
12.
go back to reference Kolamunnage-Dona, R., Powell, C., & Williamson, P. R. (2016). Modelling variable dropout in randomised controlled trials with longitudinal outcomes: Application to the MAGNETIC study. Trials, 17, 222.CrossRef Kolamunnage-Dona, R., Powell, C., & Williamson, P. R. (2016). Modelling variable dropout in randomised controlled trials with longitudinal outcomes: Application to the MAGNETIC study. Trials, 17, 222.CrossRef
13.
go back to reference Conroy, T., Galais, M.-P., Raoul, J.-L., et al. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. The Lancet Oncology, 15, 305–314.CrossRef Conroy, T., Galais, M.-P., Raoul, J.-L., et al. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. The Lancet Oncology, 15, 305–314.CrossRef
14.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life Instrument for Use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute, 85, 365–376.CrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life Instrument for Use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute, 85, 365–376.CrossRef
15.
go back to reference Fayers, P., Aaronson, N. K., & Bjordal, K., et al. (2001). EORTC QLQ-C30 scoring manual. 3rd ed. European Organisation for Research and Treatment of Cancer. Fayers, P., Aaronson, N. K., & Bjordal, K., et al. (2001). EORTC QLQ-C30 scoring manual. 3rd ed. European Organisation for Research and Treatment of Cancer.
16.
go back to reference Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., et al. (2017). Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer. European Journal of Cancer, 84, 239–249.CrossRef Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., et al. (2017). Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer. European Journal of Cancer, 84, 239–249.CrossRef
17.
go back to reference Therasse, P., Arbuck, S. G., Eisenhauer, E. A., et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst, 92, 205–216.CrossRef Therasse, P., Arbuck, S. G., Eisenhauer, E. A., et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst, 92, 205–216.CrossRef
18.
go back to reference Rizopoulos, D. (2010). JM: An R package for the joint modelling of longitudinal and time-to-event data. Journal of Statistical Software, Articles, 35, 1–33. Rizopoulos, D. (2010). JM: An R package for the joint modelling of longitudinal and time-to-event data. Journal of Statistical Software, Articles, 35, 1–33.
19.
go back to reference Rizopoulos, D. (2012). Joint models for longitudinal and time-to-event data: With applications in R. Chapman and Hall/CRC. Rizopoulos, D. (2012). Joint models for longitudinal and time-to-event data: With applications in R. Chapman and Hall/CRC.
20.
go back to reference Crowther, M. J., & Lambert, P. C. (2013). Simulating biologically plausible complex survival data. Statist Med, 32, 4118–4134.CrossRef Crowther, M. J., & Lambert, P. C. (2013). Simulating biologically plausible complex survival data. Statist Med, 32, 4118–4134.CrossRef
21.
go back to reference Crowther, M. J., & Lambert, P. C. (2012). Simulating complex survival data. The Stata Journal, 12, 674–687.CrossRef Crowther, M. J., & Lambert, P. C. (2012). Simulating complex survival data. The Stata Journal, 12, 674–687.CrossRef
22.
go back to reference Little, R. J., D’agostino, R., Cohen, M. L., et al. (2012). The prevention and treatment of missing data in clinical trials. New England Journal of Medicine, 367, 1355–1360.CrossRef Little, R. J., D’agostino, R., Cohen, M. L., et al. (2012). The prevention and treatment of missing data in clinical trials. New England Journal of Medicine, 367, 1355–1360.CrossRef
23.
go back to reference Calvert, M., Blazeby, J., Altman, D. G., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO Extension. JAMA, 309, 814–822.CrossRef Calvert, M., Blazeby, J., Altman, D. G., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO Extension. JAMA, 309, 814–822.CrossRef
24.
go back to reference Stockler, M. R., Hilpert, F., Friedlander, M., et al. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 32, 1309.CrossRef Stockler, M. R., Hilpert, F., Friedlander, M., et al. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 32, 1309.CrossRef
25.
go back to reference Powney, M., Williamson, P., Kirkham, J., et al. (2014). A review of the handling of missing longitudinal outcome data in clinical trials. Trials, 15, 237.CrossRef Powney, M., Williamson, P., Kirkham, J., et al. (2014). A review of the handling of missing longitudinal outcome data in clinical trials. Trials, 15, 237.CrossRef
26.
go back to reference Ediebah, D. E., Galindo-Garre, F., Uitdehaag, B. M. J., et al. (2015). Joint modeling of longitudinal health-related quality of life data and survival. Quality of Life Research, 24, 795–804.CrossRef Ediebah, D. E., Galindo-Garre, F., Uitdehaag, B. M. J., et al. (2015). Joint modeling of longitudinal health-related quality of life data and survival. Quality of Life Research, 24, 795–804.CrossRef
Metagegevens
Titel
Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials
Auteurs
Benjamin Cuer
Thierry Conroy
Beata Juzyna
Sophie Gourgou
Caroline Mollevi
Célia Touraine
Publicatiedatum
24-11-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2022
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-03040-8

Andere artikelen Uitgave 5/2022

Quality of Life Research 5/2022 Naar de uitgave